HEALTH AND SAFETY

» Drug, Devices, and Supplements

» Physician Accountability

» Consumer Product Safety

» Worker Safety

» Health Care Delivery

» Auto and Truck Safety

» Global Access to Medicines

» Infant Formula Marketing

 

More Information on Ethics and Clinical Trials

More information on surfactant (Surfaxin)

Press Release: Placebo-Controlled Drug Trial in Latin America Redesigned

Company Will Provide Active Treatment to All Infants

April 4, 2001

WASHINGTON, D.C. -- Following a campaign by Public Citizen, Discovery Laboratories Inc. of Doylestown, Penn., has redesigned its study of Surfaxin, its brand of the drug surfactant, which is used to treat Respiratory Distress Syndrome (RDS) in premature infants. Under the new design, no infants will receive a placebo.

"This should make it clear to all clinical researchers that developing countries are not to be used as a dumping ground for unethical research," said Dr. Peter Lurie, deputy director of Public Citizen's Health Research Group. "There should be no question now that exploiting the poverty of developing country residents is completely unacceptable. We hope that no company will be so foolhardy as to consider such exploitative research again."

On Feb. 22, 2001, Public Citizen wrote to Health and Human Services Secretary Tommy Thompson urging him to prevent the Food and Drug Administration (FDA) from endorsing a study design in which hundreds of infants would receive placebos instead of one of the four FDA-approved surfactants. Another study planned by the company in Europe gave all infants either the company's surfactant or a known effective surfactant. That study did not use placebos. 

The Latin America study was to have been conducted in at least one of four countries (Mexico, Bolivia, Ecuador and Peru), even though the company acknowledged that surfactant is available to some infants in those countries. The company planned to conduct the study in hospitals without the drug. As the FDA admitted, "Conduct of a placebo controlled surfactant trial for premature infants with RDS is considered unethical in the USA."

The proposed trial was in clear contravention of the October 2000 Declaration of Helsinki, which requires that, "The benefits, risks, burdens and effectiveness of a new method should be tested against those of the best current prophylactic, diagnostic, and therapeutic methods." The new trial design would comply with the Declaration.

Copyright © 2016 Public Citizen. Some rights reserved. Non-commercial use of text and images in which Public Citizen holds the copyright is permitted, with attribution, under the terms and conditions of a Creative Commons License. This Web site is shared by Public Citizen Inc. and Public Citizen Foundation. Learn More about the distinction between these two components of Public Citizen.


Public Citizen, Inc. and Public Citizen Foundation

 

You can support the fight for greater government and corporate accountability through a donation to either Public Citizen, Inc., or Public Citizen Foundation, Inc.

Public Citizen lobbies Congress and federal agencies to advance Public Citizen’s mission of advancing government and corporate accountability. When you make a contribution to Public Citizen, you become a member of Public Citizen, showing your support and entitling you to benefits such as Public Citizen News. Contributions to Public Citizen are not tax-deductible.

Public Citizen Foundation focuses on research, public education, and litigation in support of our mission. By law, the Foundation can engage in only very limited lobbying. Contributions to Public Citizen Foundation are tax-deductible.